- AbCellera Biologics Q1 Earnings Call Highlights
May 11, 2026 · marketbeat.com
AbCellera Biologics NASDAQ: ABCL said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation for multiple clinical catalysts expected over the next two years.
- AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates
May 11, 2026 · zacks.com
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.15 per share a year ago.
- AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
May 11, 2026 · businesswire.com
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635.
- ABCELLERA REPORTS Q1 2026 BUSINESS RESULTS & ANNOUNCES POSITIVE INTERIM PHASE 1 CLINICAL DATA FOR ABCL635
May 11, 2026
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)---- $ABCL--ABCELLERA REPORTS Q1 2026 BUSINESS RESULTS & ANNOUNCES POSITIVE INTERIM PHASE 1 CLINICAL DATA FOR ABCL635.
- Why AbCellera Biologics (ABCL) Is Up 16.1% After ABCL635 Trial Momentum Builds Ahead Of Data
May 7, 2026
In recent days, attention has centred on AbCellera Biologics ahead of its upcoming Q1 earnings call and the May 11, 2026 Phase 1 interim data update for ABCL635, a clinical candidate targeting menopause-related vasomotor symptoms. Investor optimism has been reinforced by analyst commentary on the potential competitiveness of ABCL635, growing insider and institutional interest, and AbCellera’s progress in advancing 19 molecules into clinical development across internal and partnered programs, including work with Eli Lilly. Next, we’ll examine how the upcoming ABCL635 Phase 1 data readout could influence AbCellera’s investment narrative and long-term pipeline outlook.
We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
AbCellera Biologics Investment Narrative Recap
To own AbCellera, you need to believe its antibody discovery platform and growing clinical pipeline can eventually translate into meaningful, less volatile revenue, despite ongoing losses. The key near term catalyst remains the ABCL635 Phase 1 interim update on May 11, 2026, which could shape sentiment on its menopause program. The recent optimism around ABCL635 and insider buying supports interest in this catalyst, but does not materially reduce the clinical or financial risks.
The most relevant recent announcement is AbCellera’s plan to share interim Phase 1 data for ABCL635 on the upcoming Q1 2026 earnings call. This ties the clinical and financial story together, as investors will hear both early safety/target engagement signals for ABCL635 and an update on revenue and losses in the same event. How the market weighs clinical progress alongside persistent negative earnings will likely frame expectations for the next phase of the stock’s story.
Yet behind the excitement around ABCL635, investors should be aware that the company’s widening losses and reliance on future milestones leave it exposed if...
Read the full narrative on AbCellera Biologics (it's free!)
AbCellera Biologics' narrative projects $123.3 million revenue and $17.5 million earnings by 2028. This requires 55.4% yearly revenue growth and a $183.2 million earnings increase from $-165.7 million today.
Uncover how AbCellera Biologics' forecasts yield a $9.83 fair value, a 104% upside to its current price.
Exploring Other PerspectivesABCL 1-Year Stock Price Chart
Some of the lowest ranked analysts were far more cautious, assuming revenue could shrink about 27.7% a year and still not see profits within three years, which contrasts sharply with the optimism around upcoming ABCL635 data and highlights how widely views on AbCellera’s risk and reward can differ.
Story Continues
Explore 9 other fair value estimates on AbCellera Biologics - why the stock might be worth just $7.00!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
A great starting point for your AbCellera Biologics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision. Our free AbCellera Biologics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbCellera Biologics' overall financial health at a glance.
Seeking Other Investments?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
Find 49 companies with promising cash flow potential yet trading below their fair value. The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ABCL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- JonesResearch Reiterates Buy on AbCellera Biologics (ABCL)
May 5, 2026
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the
8 Best Healthcare AI Stocks to Buy According to Analysts.
On April 22, 2026, JonesResearch highlighted AbCellera Biologics Inc. (NASDAQ:ABCL), noting that if its ABCL635 candidate demonstrates clean safety with no hepatic signals and achieves target engagement comparable to Veohah and Lynkuet, the therapy could be “very competitive.” The firm has reiterated its Buy rating and $11 price target on AbCellera Biologics Inc. (NASDAQ:ABCL) ahead of a Phase 1 update expected on May 11, 2026.
Just earlier in the month of April, JonesResearch analyst Debanjana Chatterjee initiated coverage of AbCellera Biologics Inc. (NASDAQ:ABCL) with a Buy rating and $11 price target on the shares. The firm has said that AbCellera Biologics Inc. (NASDAQ:ABCL)’s antibody discovery platform has advanced 19 molecules into clinical development across both internal and partnered programs spanning multiple therapeutic areas, with its capabilities “best illustrated” through its collaboration with Eli Lilly.JonesResearch Reiterates Buy on AbCellera Biologics (ABCL)
AbCellera Biologics Inc. (NASDAQ:ABCL) develops antibody-based therapies targeting diseases with unmet medical needs.
While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- AbCellera Biologics Among 3 Promising Penny Stocks
May 1, 2026
In the last week, the market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings forecast to grow by 16% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still offer significant opportunities when built on solid financials. In this article, we explore three penny stocks that combine balance sheet strength with potential for outsized gains, providing investors a chance to discover hidden value in quality companies.
Top 10 Penny Stocks In The United States
Name Share Price Market Cap Financial Health Rating WM Technology (MAPS) $0.326 $62.29M ★★★★★★ LexinFintech Holdings (LX) $2.11 $343.26M ★★★★★★ FinVolution Group (FINV) $4.96 $1.23B ★★★★★☆ Information Services Group (III) $3.11 $192.6M ★★★★★★ Golden Growers Cooperative (GGRO.U) $5.00 $77.45M ★★★★★★ Niagen Bioscience (NAGE) $4.73 $381.98M ★★★★★★ Cricut (CRCT) $4.31 $898.36M ★★★★★★ Village Farms International (VFF) $2.85 $324.59M ★★★★★★ SIGA Technologies (SIGA) $7.80 $324.55M ★★★★★★ BAB (BABB) $0.91 $6.54M ★★★★★★
Click here to see the full list of 347 stocks from our US Penny Stocks screener.
We're going to check out a few of the best picks from our screener tool.
AbCellera Biologics
Simply Wall St Financial Health Rating: ★★★★★★
Overview: AbCellera Biologics Inc. focuses on discovering and developing antibody-based medicines for unmet medical needs in the United States, with a market cap of approximately $1.16 billion.
Operations: The company's revenue is derived from the discovery and development of antibodies, totaling $75.13 million.
Market Cap: $1.16B
AbCellera Biologics Inc. is navigating the penny stock landscape with a market cap of US$1.16 billion and revenues reaching US$75.13 million, marking growth from prior periods despite ongoing unprofitability and increasing losses over five years. The company remains debt-free, with short-term assets comfortably covering liabilities, providing a cash runway exceeding three years even if cash flow continues to decrease historically by 40.2% annually. Recent announcements include interim results for ABCL635 in Phase 1 trials targeting VMS symptoms associated with menopause, highlighting its potential in advancing antibody therapeutics while maintaining shareholder value without significant dilution recently.
Dive into the specifics of AbCellera Biologics here with our thorough balance sheet health report. Gain insights into AbCellera Biologics' outlook and expected performance with our report on the company's earnings estimates.ABCL Financial Position Analysis as at May 2026
Cytek Biosciences
Simply Wall St Financial Health Rating: ★★★★★☆
Story Continues
Overview: Cytek Biosciences, Inc. is a cell analysis solutions company offering tools for biomedical research and clinical applications, with a market cap of approximately $570.76 million.
Operations: The company generates revenue of $201.49 million from its Scientific & Technical Instruments segment.
Market Cap: $570.76M
Cytek Biosciences, Inc. is navigating the penny stock sector with a market cap of US$570.76 million and revenue of US$201.49 million in 2025, despite being unprofitable with increasing losses over five years at 67.6% annually. The company maintains a strong liquidity position, as short-term assets exceed both short-term and long-term liabilities, and it has more cash than total debt, offering a cash runway exceeding three years based on current free cash flow levels. Recent developments include filing a shelf registration for US$28.22 million and setting revenue guidance between US$205 million to US$212 million for 2026.
Click here to discover the nuances of Cytek Biosciences with our detailed analytical financial health report. Review our growth performance report to gain insights into Cytek Biosciences' future.CTKB Financial Position Analysis as at May 2026
FinVolution Group
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: FinVolution Group is an investment holding company that operates in the online consumer finance industry across the People’s Republic of China, Indonesia, and internationally, with a market cap of approximately $1.23 billion.
Operations: The company generates revenue of CN¥13.57 billion from its Internet Software & Services segment.
Market Cap: $1.23B
FinVolution Group, with a market cap of $1.23 billion, operates in the online consumer finance sector and has shown stable financial performance despite recent challenges. The company reported annual revenue of CN¥13.57 billion for 2025 and anticipates a slight revenue decline for 2026, ranging from RMB11.5 billion to RMB12.9 billion. Its strong balance sheet features short-term assets exceeding liabilities significantly and cash surpassing total debt levels, indicating robust liquidity management. While earnings growth over the past year was modest at 6.7%, its profit margins have improved slightly, reflecting high-quality earnings amidst industry volatility.
Unlock comprehensive insights into our analysis of FinVolution Group stock in this financial health report. Learn about FinVolution Group's future growth trajectory here.FINV Debt to Equity History and Analysis as at May 2026
Seize The Opportunity
Click through to start exploring the rest of the 344 US Penny Stocks now. Ready To Venture Into Other Investment Styles? We've found 14 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ABCLCTKB and FINV.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- JonesResearch Initiates Coverage of AbCellera Biologics Inc. (ABCL)
Apr 20, 2026
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best stocks under $5 with huge upside potential. On April 9, JonesResearch initiated coverage of AbCellera Biologics Inc. (NASDAQ:ABCL) with a Buy rating and set a $11 price target. The firm stated that the company’s validated antibody discovery platform has advanced 19 molecules into the clinic across internal and partnered programs spanning several indications, adding that AbCellera Biologics Inc.’s (NASDAQ:ABCL) capabilities are “best illustrated” by its collaboration with Eli Lilly.Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now?
In its financial results for the full year 2025, AbCellera Biologics Inc. (NASDAQ:ABCL) reported that it successfully delivered on all its corporate priorities while transitioning to a clinical-stage biotech company and ending the year with around $700 million in available liquidity to execute on its strategy. For the full year, AbCellera Biologics Inc. (NASDAQ:ABCL) earned $75.1 million in total revenue and generated a net loss of $146.4 million, compared to a net loss of $162.9 million in the prior year period.
AbCellera Biologics (NASDAQ:ABCL) solves antibody discovery problems by integrating data science, technology, infrastructure, and interdisciplinary teams. It develops and discovers antibody medicines for indications across therapeutic areas, including metabolic and endocrine conditions, cancer, and autoimmune disorders. It boasts technology platforms that unlock drug classes, modalities, and targets, including T-cell engagers, peptide-MHCs, and transmembrane proteins.
While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
Apr 20, 2026 · businesswire.com
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call.
- ABCELLERA TO HIGHLIGHT PHASE 1 CLINICAL DATA FOR ABCL635 DURING UPCOMING FIRST QUARTER 2026 EARNINGS CALL
Apr 20, 2026
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)---- $ABCL--ABCELLERA TO HIGHLIGHT PHASE 1 CLINICAL DATA FOR ABCL635 DURING UPCOMING FIRST QUARTER 2026 EARNINGS CALL.
